Phase 3 Readout
PFE: Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot
September 19, 2026 · enzalutamide. BioSniper AI can trace the company-impact path without requiring you to write the research question.
- Event date
- September 19, 2026
- Company
- PFIZER INC (PFE)
- Drug
- enzalutamide
BioSniper AIPage evidence connected
Prepared research question
What could this event change, and which evidence should be watched next?
Run cited research
Traceable citations · Unknowns marked
Phase 3 Readout~month
Phase 3 Topline: A Phase 3, Randomized, Efficacy and Safety Study of Enzalutamide Plus Leuprolide, Enzalutamide Monot
- Company
- PFIZER INC (PFE)
- Drug
- enzalutamide
- Indication
- Prostate Cancer; Hormone Sensitive Prostate Cancer; Cancer of the Prostate